Atlas Venture Associates IX, LLC
CIK 1671207 · last filed 2020-12-21
Atlas Venture Associates IX, LLC is a corporate insider who has filed 6 SEC Form 4 insider transactions across 3 companies since 2016. The most recent filing shows the insider sold $92.3M of SURF on Dec 21, 2020. Across all open-market trades the lifetime net is −$85.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $43.5M across reported positions. The firm reports its address in Boston, MA. 11 SEC filings were submitted jointly with Atlas Venture Fund IX, L.P.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SURF price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
BOSTON, MA 02118
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Surface Oncology, Inc. (SURF) Delisted | 10%+ Owner | 2,945,453 | $1.07 | $3.15M | -$87.81M | 2 | 2020-12-21 |
| Cogent Biosciences, Inc. (UMRX) Delisted | 10%+ Owner | 3,267,483 | — | — | $3.39M | 1 | 2018-04-03 |
| NTLA | 10%+ Owner | 3,729,788 | $11.65 | $43.45M | -$587.7K | 3 | 2017-03-13 |
Recent Filings
6 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-12-21 | Surface Oncology, Inc. (SURF) Delisted | Sell (S) | −5,100,000 | -$92.31M | EDGAR |
| 2018-04-23 | Surface Oncology, Inc. (SURF) Delisted | Mixed | +9,845,451 | $4.50M | EDGAR |
| 2018-04-03 | Cogent Biosciences, Inc. (UMRX) Delisted | Mixed | +10,084,605 | $3.39M | EDGAR |
| 2017-03-13 | NTLA | Sell (S) | −42,264 | -$587.7K | EDGAR |
| 2017-03-07 | NTLA | Other (J) | −2,100,000 | $0 | EDGAR |
| 2016-05-11 | NTLA | Conv (C) | +13,289,364 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.